TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28115424

Group type: EXPERIMENTAL
Intervention: Schoolyard renovation, mandatory outdoor recess, increased adult supervision and support
Number of subjects: 0
Study: 26322787

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training
Number of subjects: 304

Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 304
Study: 23257975

Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/day)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 202
Study: 20872083

Group type: EXPERIMENTAL
Intervention: Population-based informatics system implemented in intervention practices
Number of subjects: 6070

Group type: COMPARATOR
Intervention: Control practices with standard electronic health record reminders
Number of subjects: 6070
Study: 19996078

Group type: EXPERIMENTAL
Intervention: low-frequency repetitive transcranial magnetic stimulation (lfrTMS)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: cathodal transcranial direct current stimulation (tDCS)
Number of subjects: 7
Study: 17459480

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 200

Group type: COMPARATOR
Intervention: LTFC (Latanoprost and Timolol Fixed Combination)
Number of subjects: 200
Study: 15226164

Group type: EXPERIMENTAL
Intervention: PTSD (n = 4348)
Number of subjects: 30865

Group type: EXPERIMENTAL
Intervention: Depression alone (n = 7580)
Number of subjects: 30865

Group type: COMPARATOR
Intervention: Neither condition (n = 18,937)
Number of subjects: 30865
Study: 11704081

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dim light therapy (DLT)
Number of subjects: 23
Study: 9606848

Group type: EXPERIMENTAL
Intervention: Antioxidant metalloproteins (superoxide dismutase, catalase, ceruloplasmin, transferrin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prooxidant metalloproteins (cytochromes b5, b558III, b558IV, suprol)
Number of subjects: 0
Study: 8199567

Group type: EXPERIMENTAL
Intervention: High-dose cyclosporin (CsA)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Low-dose cyclosporin (CsA)
Number of subjects: 91

Group type: COMPARATOR
Intervention: M1‐M3 FAB subtypes
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: M4‐M6 FAB subtypes
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Long interval (> or = 180 days) between diagnosis and BMT
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 91
Study: 3587902

Group type: EXPERIMENTAL
Intervention: Concurrent multiagent chemotherapy and orbital radiation therapy after initial partial tumor resection
Number of subjects: 127

Group type: COMPARATOR
Intervention: Initial partial tumor resection
Number of subjects: 127

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 127
Study: 29606517

Group type: EXPERIMENTAL
Intervention: F4/AS01B HIV-1 vaccine candidate
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 27852717

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 80
Study: 24356715

Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19673954

Group type: EXPERIMENTAL
Intervention: Early placement protocol (4 weeks after tooth extraction)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed placement protocol (12 weeks after tooth extraction)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Early placement protocol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed placement protocol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both early and delayed protocols
Number of subjects: 20
Study: 20802351

Group type: EXPERIMENTAL
Intervention: AZD6244 (100 mg oral free-base suspension twice daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m2 intravenous once every 3 weeks)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: AZD6244
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pemetrexed
Number of subjects: 84
Study: 19054833

Group type: EXPERIMENTAL
Intervention: Nicotinell TTS 20 patch (single dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nicotinell TTS 20 patch (multiple doses over 4 days)
Number of subjects: 24
Study: 15690307

Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbohydrate supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Protein and Carbohydrate)
Number of subjects: 0
Study: 14646626

Group type: EXPERIMENTAL
Intervention: Cisplatin at a dose of 150 mg/m2 and WR‐2721 at a dose of 910 mg/m2
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cisplatin alone at a dose of 120 mg/m2
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cisplatin with WR‐2721
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 94
Study: 10671837

Group type: EXPERIMENTAL
Intervention: Background infusion of 5 ml x h‐1 (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No background infusion (Group N)
Number of subjects: 42
Study: 8813987

Group type: EXPERIMENTAL
Intervention: Endoprosthesis (BE) with a 7F double-pigtail endoprosthesis and < 0.75 cm sphincterotomy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Duct clearance (DC) with standard 1.25-1.50 cm sphincterotomy and stone extraction by balloon or basket, with or without mechanical lithotripsy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Endoprosthesis (BE)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Duct clearance (DC)
Number of subjects: 43
Study: 1594261

Group type: EXPERIMENTAL
Intervention: Topical aspirin/diethyl ether (ADE) mixture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Indomethacin and diclofenac drug/ether mixtures
Number of subjects: 45
Study: 6705752

Group type: EXPERIMENTAL
Intervention: Flunarizine (add-on therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 30925733

Group type: EXPERIMENTAL
Intervention: Pomegranate Extract (PE)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 26
Study: 28866294

Group type: EXPERIMENTAL
Intervention: Bayesian response adaptive randomization (BRAR) algorithms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed equal allocation design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Properly selected BRAR algorithm
Number of subjects: 0
Study: 26044257

Group type: EXPERIMENTAL
Intervention: 16 weeks of combined physical exercise training (EG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No specifically orientated physical activity (CG)
Number of subjects: 57
Study: 24300768

Group type: EXPERIMENTAL
Intervention: Rinorin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 21911866

Group type: COMPARATOR
Intervention: Synchronous arm cranking (SYN)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Asynchronous arm cranking (ASY)
Number of subjects: 32
Study: 19882589

Group type: COMPARATOR
Intervention: Subconjunctival regenerative factor-rich plasma (RFRP) for moderate burns
Number of subjects: 35

Group type: COMPARATOR
Intervention: Subconjunctival regenerative factor-rich plasma (RFRP) for severe burns
Number of subjects: 35

Group type: COMPARATOR
Intervention: Subconjunctival regenerative factor-rich plasma (RFRP)
Number of subjects: 35
Study: 16731878

Group type: EXPERIMENTAL
Intervention: PACT case management in addition to usual medical and nursing home care
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 62
Study: 14504005

Group type: EXPERIMENTAL
Intervention: Alprostadil 500 g cream
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Alprostadil 1000 g cream
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Alprostadil 1500 g cream
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 94
Study: 10348802

Group type: EXPERIMENTAL
Intervention: Single-dose disulfiram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 0
Study: 8547045

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) calculated according to body weight (0.6 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) calculated according to body surface area (25 mg/m2)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 8-methoxypsoralen (8-MOP) doses of 40 or 50 mg based on body surface area
Number of subjects: 41
Study: 1777376

Group type: EXPERIMENTAL
Intervention: Nisoldipine + Propranolol
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nisoldipine + Atenolol
Number of subjects: 2
Study: 7017074

Group type: EXPERIMENTAL
Intervention: 10% ointment from 95% ethanol extract of Lupinus termis seeds
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.02% flumethasone pivalate ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6519740

Group type: EXPERIMENTAL
Intervention: Diet restricted in energy (fats and carbohydrates) but unrestricted in sodium (Group 1), n = 13
Number of subjects: 23

Group type: COMPARATOR
Intervention: Diet restricted in energy and sodium (Group 2), n = 10
Number of subjects: 23
Study: 30577819

Group type: EXPERIMENTAL
Intervention: Immediate Intervention (n=30) received a Fitbit® Flex™ and four bi-weekly activity counselling sessions
Number of subjects: 61

Group type: COMPARATOR
Intervention: Delayed Intervention (n=31) received the same intervention two months later
Number of subjects: 61
Study: 27566633

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 553
Study: 24580124

Group type: EXPERIMENTAL
Intervention: Surgical intervention including tympanic effusion incision or catheterization, adenoidectomy and/or bilateral tonsillectomy for group 1 (0-6 years old) treated for approximately 2 months.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Surgical intervention including tympanic effusion incision or catheterization, adenoidectomy and/or bilateral tonsillectomy for group 2 (7-15 years old) treated for 10 months.
Number of subjects: 46
Study: 22500821

Group type: EXPERIMENTAL
Intervention: Pegnivacogin 0.5 mg kg(‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pegnivacogin 1.0 mg kg(‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pegnivacogin 3.0 mg kg(‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pegnivacogin 2.0 mg kg(‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Anivamersen (single-dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Anivamersen (multidose)
Number of subjects: 36
Study: 20399240

Group type: EXPERIMENTAL
Intervention: DTaP/Hib combination vaccine (3 doses at 3, 4, and 5 months)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Separate licensed DTaP vaccine and Hib conjugate vaccine (3 doses at 3, 4, and 5 months)
Number of subjects: 720
Study: 19023839

Group type: EXPERIMENTAL
Intervention: ASPIRE curriculum
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Standard care (National Cancer Institute's Clearing the Air self‐help booklet)
Number of subjects: 1160
Study: 16012942

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 232

Group type: COMPARATOR
Intervention: Ethanol injection
Number of subjects: 232
Study: 12696086

Group type: EXPERIMENTAL
Intervention: Radiofrequency electromagnetic fields (RF EMF) exposure (900 MHz; SAR 1 W/kg) during sleep
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Radiofrequency electromagnetic fields (RF EMF) exposure (900 MHz; SAR 1 W/kg) prior to sleep
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control condition with sham exposure
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Radiofrequency electromagnetic fields (RF EMF) exposure during sleep
Number of subjects: 2
Study: 10321402

Group type: EXPERIMENTAL
Intervention: Postal health needs questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no postal questionnaire)
Number of subjects: 0
Study: 8806255

Group type: EXPERIMENTAL
Intervention: Early treatment with antiretroviral drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 0
Study: 1988512

Group type: EXPERIMENTAL
Intervention: Bivalent attenuated (CR) vaccine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated (TI) vaccine
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 7158268

Group type: EXPERIMENTAL
Intervention: EMLA (eutectic mixture of prilocaine and lidocaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31022932

Group type: EXPERIMENTAL
Intervention: Weight loss (>2 kg, n = 74)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Weight gain (>2 kg, n = 58)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Weight stable (±2 kg, n = 74)
Number of subjects: 206
Study: 30580260

Group type: EXPERIMENTAL
Intervention: SIGN head injury guidelines (introduced in 2000)
Number of subjects: 571221

Group type: EXPERIMENTAL
Intervention: 4-hour ED target (introduced in 2004)
Number of subjects: 571221

Group type: EXPERIMENTAL
Intervention: SIGN head injury guidelines (introduced in 2009)
Number of subjects: 571221

Group type: EXPERIMENTAL
Intervention: CT imaging for head injuries (identified by guidelines)
Number of subjects: 571221
Study: 27371185

Group type: EXPERIMENTAL
Intervention: Immediate total-body CT scanning
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Standard work-up
Number of subjects: 1403
Study: 24555576

Group type: EXPERIMENTAL
Intervention: PDE-5 inhibitors in adequately blinded trials
Number of subjects: 23877

Group type: EXPERIMENTAL
Intervention: PDE-5 inhibitors in inadequately blinded trials
Number of subjects: 23877

Group type: COMPARATOR
Intervention: Placebo in adequately blinded trials
Number of subjects: 23877

Group type: COMPARATOR
Intervention: Placebo in inadequately blinded trials
Number of subjects: 23877

Group type: COMPARATOR
Intervention: Placebo groups with participants naïve to the intervention
Number of subjects: 23877

Group type: COMPARATOR
Intervention: Placebo groups with participants having prior experience
Number of subjects: 23877

Group type: EXPERIMENTAL
Intervention: Intervention groups with participants naïve to the intervention
Number of subjects: 23877

Group type: EXPERIMENTAL
Intervention: Intervention groups with participants having prior experience
Number of subjects: 23877

Group type: COMPARATOR
Intervention: Unblinding effect on placebo scores
Number of subjects: 23877

Group type: EXPERIMENTAL
Intervention: Unblinding effect on intervention scores
Number of subjects: 23877
Study: 22206712

Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEV)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No volatile anesthesia (group O)
Number of subjects: 92
Study: 20975577

Group type: EXPERIMENTAL
Intervention: e-diary
Number of subjects: 69

Group type: COMPARATOR
Intervention: paper diary
Number of subjects: 69
Study: 17279539

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16216094

Group type: EXPERIMENTAL
Intervention: 400 microg dose of inhaler (powder inhaler)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 400 microg dose of inhaler (remaining powder)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (10% sucrose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall (all inhalers)
Number of subjects: 10
Study: 12603781

Group type: EXPERIMENTAL
Intervention: 3 hours TIB
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5 hours TIB
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 7 hours TIB
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 9 hours TIB
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Recovery after 3 hours TIB
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Recovery after 5 hours TIB
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Recovery after 7 hours TIB
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Recovery after 9 hours TIB
Number of subjects: 66
Study: 10096691

Group type: EXPERIMENTAL
Intervention: Casewise estimator under random or complete ascertainment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pairwise estimator under random or complete ascertainment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Casewise estimator under incomplete ascertainment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pairwise estimator under incomplete ascertainment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probandwise estimator under incomplete ascertainment
Number of subjects: 0
Study: 7553006

Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 47

Group type: COMPARATOR
Intervention: Open release
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 2150105

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (first- or second-generation cephalosporins)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 17
Study: 6941373

Group type: EXPERIMENTAL
Intervention: Combined injection of 3.0 mg/kg cimetidine and 0.3 mg/kg pirenzepine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined injection of 1.5 mg/kg cimetidine, 0.075 and 0.15 mg/kg pirenzepine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31286732

Group type: EXPERIMENTAL
Intervention: Umbilical needling therapy of I-Ching; treatment at 1 PM to 3 PM, once a day for 20 days.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine treatment of western medicine combined with TCM decoction; control group.
Number of subjects: 48
Study: 26756171

Group type: EXPERIMENTAL
Intervention: 200U onabotulinum toxin A (onaBoNTA)
Number of subjects: 122
Study: 25769541

Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide and low-dose dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed cycles of lenalidomide and low-dose dexamethasone for 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed cycles of melphalan, prednisone, thalidomide for 18 months
Number of subjects: 0
Study: 23532145

Group type: EXPERIMENTAL
Intervention: Warm environment (33 °C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cold environment (7 °C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Room temperature environment (20 °C)
Number of subjects: 12
Study: 21500011

Group type: EXPERIMENTAL
Intervention: Physical activity (three times weekly)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Mental activity (three times weekly)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Adherence (time spent on course attendance)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Activity mode (physical vs. mental)
Number of subjects: 229
Study: 18387342

Group type: EXPERIMENTAL
Intervention: Composite Scale of Morningness (CSM)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Morningness‐Eveningness Questionnaire (MEQ)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: CSM and MEQ
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: CSM
Number of subjects: 456

Group type: COMPARATOR
Intervention: MEQ
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: T-scores (mean of 50 and standard deviation of 10)
Number of subjects: 456
Study: 16965431

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment twice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Dithranol cream once daily
Number of subjects: 106
Study: 14984440

Group type: COMPARATOR
Intervention: Betamethasone (60 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methylprednisolone (400 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 24
Study: 10701382

Group type: EXPERIMENTAL
Intervention: Visiting nurse group
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 142
Study: 9342783

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT; 3 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Melatonin (MLT; 9 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Melatonin (MLT; 3 mg or 9 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8261880

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 4041370

Group type: EXPERIMENTAL
Intervention: Cyclosporin A alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cyclosporin A in combination with antilymphocyte serum
Number of subjects: 12
Study: 29561377

Group type: EXPERIMENTAL
Intervention: 4.5-mm-wide titanium implant
Number of subjects: 57

Group type: COMPARATOR
Intervention: 3.75-mm-wide titanium implant
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both implants
Number of subjects: 57
Study: 26911970

Group type: EXPERIMENTAL
Intervention: Human placental extract (HPE)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 78
Study: 24661578

Group type: EXPERIMENTAL
Intervention: Piezosurgery using a high‐speed handpiece and a piezotome
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular surgery using a high‐speed handpiece and an elevator
Number of subjects: 20
Study: 24201230

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Nondepressed controls
Number of subjects: 69
Study: 21613553

Group type: EXPERIMENTAL
Intervention: Yogurt consumption
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Yogurt consumption >100 g/d
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Total dairy product, milk, and cheese consumption
Number of subjects: 1080
Study: 19549290

Group type: EXPERIMENTAL
Intervention: Masitinib 3 mg/kg per day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Masitinib 6 mg/kg per day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Masitinib
Number of subjects: 43